← All stocks

Intellia Therapeutics, Inc.

NTLA Net buying
CIK 0001652130 #2130 in the set updated 17 Sep 2026
Bought (12 mo)
$1.40M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$2.17M
$371.01K on a plan · $836.38K straight out of an exercise
Sold at will
$965.81K
13 of 19 sales
Net
−$770.70K
+$436.69K against sales at will

By person

16 insiders · 21 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
LEONARD JOHN M
President and CEO
$1.44M (6) scheduled
−$1.44M
1,147,064
0.8186%
$14.91M
+19.5%
Cohen Fred E
Director
$1.40M (1)
+$1.40M
216,653
0.1546%
$2.82M
+338.1%
Dulac Edward J III
EVP, Chief Financial Officer
$234.19K (3)
−$234.19K
148,175
0.1057%
$1.93M
+123.4%
BASTA JAMES
EVP, General Counsel
$112.44K (2)
−$112.44K
156,794
0.1119%
$2.04M
+70.5%
Lebwohl David
EVP, Chief Medical Officer
$109.63K (1)
−$109.63K
131,192
0.0936%
$1.71M
+36.2%
Dube Michael P
VP, Chief Accounting Officer
$104.36K (3)
−$104.36K
66,886
0.0477%
$869.52K
+36.4%
Clark Eliana
EVP, Chief Technical Officer
$96.00K (2)
−$96.00K
93,864
0.0670%
$1.22M
+26.3%
Schultes Birgit C
EVP, Chief Scientific Officer
$78.90K (2)
−$78.90K
137,733
0.0983%
$1.79M
+98.3%
CHASE WILLIAM J
Director
143,893
0.1027%
$1.87M
+439.1%
Sepp-Lorenzino Laura
EVP, Chief Scientific Officer
77,388
0.0552%
$1.01M
−6.6%
Hicks Derek
EVP, Chief Business Officer
59,878
0.0427%
$778.41K
−9.8%
Keresty Georgia
Director
41,083
0.0293%
$534.08K
+72.0%
Bhanji Muna
Director
36,403
0.0260%
$473.24K
+84.5%
Verwiel Frank
Director
35,148
0.0251%
$456.92K
+95.8%
GOODMAN JESSE
Director
33,559
0.0239%
$436.27K
+72.5%
Goff Brian
Director
32,609
0.0233%
$423.92K
+111.6%
Insider
Date
Role
Action
Shares
Price
Amount
LEONARD JOHN M
21 Aug 2026
President and CEO
Sold on a plan
2,785
$13.00
$36.21K
LEONARD JOHN M
20 Aug 2026
President and CEO
Sold on a plan
19,890
$12.60
$250.61K
Dulac Edward J III
2 Jul 2026
EVP, Chief Financial Officer
Sold on a plan
4,677
$18.00
$84.19K

What was left out

Form 4 filings counted 29
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 3
Sales straight out of an exercise 3
Sales at will 13
Transactions with no price 0
Shares from compensation/vesting 460,422
History held since 5 Jan 2017